by Maria Zannes | May 18, 2018 | Press Releases
MAY 14, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Peter S. Knight, founding partner of Generation Investment Management, to its Board of...
by Maria Zannes | Mar 15, 2018 | Press Releases
FEBRUARY 28, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it had been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN...
by Maria Zannes | Nov 30, 2017 | Press Releases
NOVEMBER 29, 2017 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced the appointments of Stephen Squinto, Ph.D., and Gary Rubin, CPA, to its Board of Directors. Dr. Squinto is a Venture Partner...
by Maria Zannes | May 3, 2017 | Press Releases
MAY 3, 2017 (SAN ANTONIO, TX ) bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030. The EPO patent, titled “System...
by Maria Zannes | Nov 15, 2016 | Press Releases
NOVEMBER 15, 2016 (SAN ANTONIO, TX) bioAffinity Technologies announced that the government of the Hong Kong Special Administrative Region has awarded a Certificate of Grant of Standard Patent for the Company’s proprietary CyPath© technology for the early detection of...
by Maria Zannes | Aug 24, 2016 | Press Releases
AUGUST 24, 2016 (SAN ANONIO, TX) bioAffinity Technologies today announced that it has been awarded a U.S. Patent protecting a proprietary kit that contains the CyPath® assay for the early detection of cancer and the prognosis of the patient response to cancer therapy....
